Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass

• Phase: Phase 4

Details

• Lead Sponsor: West Penn Allegheny Health System
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• hemodialysis patients

Exclusion Criteria:

• non compliance

• hyperkalemia

• pregnancy

• expected survival less than 9 months